The Wearable Diabetes Devices Market report segments the industry into Device (Continuous Glucose Monitoring Devices, Insulin Pumps), Type (Non-Invasive Glucose Monitoring Devices, Invasive Glucose Monitoring Devices), End User (Hospital/Clinics, Home/Personal), and Geography (North America, Europe, Latin America, Asia-Pacific, Middle East and Africa). Get five years of historical data and market forecasts.

The Wearable Diabetes Devices market, valued at $11 billion in 2025, is experiencing robust growth, projected to expand at a CAGR exceeding 10% from 2025 to 2033. This surge is driven by several key factors. The increasing prevalence of diabetes globally, coupled with advancements in continuous glucose monitoring (CGM) technology, fuels demand for convenient and non-invasive monitoring solutions. Miniaturization and improved accuracy of devices, along with the rising adoption of connected health platforms for remote patient monitoring and data management, contribute significantly to market expansion. Furthermore, the growing preference for personalized diabetes management and improved patient outcomes incentivize both healthcare providers and individuals to adopt wearable technologies. The market segmentation reveals substantial opportunities across durables (insulin pumps), non-invasive and invasive glucose monitoring devices, and diverse end-user segments (hospitals/clinics, home/personal use). Key players like Eversense, Medtronic, Tandem Diabetes Care, Ascensia, Insulet Corporation, Abbott, Ypsomed, and Dexcom are driving innovation and competition, further accelerating market growth. The geographical distribution of the market reflects established healthcare infrastructure and technological adoption rates. North America and Europe currently dominate, but the Asia-Pacific region is poised for significant growth, fueled by rising diabetes prevalence and increasing disposable incomes. Market restraints include the high cost of devices, potential for inaccurate readings, and concerns regarding data privacy and security. However, ongoing technological advancements, increasing healthcare expenditure, and supportive government initiatives are mitigating these challenges and fostering sustained market expansion. The forecast period (2025-2033) anticipates consistent growth, driven by the continuous evolution of technology, expansion into emerging markets, and increasing awareness of effective diabetes management strategies. The market's future trajectory hinges on sustained innovation, affordability improvements, and wider accessibility of wearable diabetes devices. Recent developments include: May 2023: The Beta Bionics iLet ACE Pump and the iLet Dosing Decision Software have been granted clearance by the U.S. Food and Drug Administration for individuals aged six and above who have type 1 diabetes. When combined with a compatible FDA-cleared integrated continuous glucose monitor (iCGM), these two devices will create a novel system known as the iLet Bionic Pancreas. This innovative automated insulin dosing (AID) system employs an algorithm to ascertain and direct the administration of insulin., March 2023: The FDA has approved the Eversense E3 Continuous Glucose Monitoring (CGM) System. This innovative system offers real-time monitoring of blood sugar (glucose) levels and tracks their trends over time. Users can conveniently access this information through a mobile app installed on their smartphone, tablet, or other compatible device.. Key drivers for this market are: Rapidly Increasing Incidence and Prevalence of Diabetes, Technological Advancements in the Market. Potential restraints include: Monopolized Supply Chain and High Cost of Devices. Notable trends are: Rising diabetes prevalence globally is driving the market in forecast years.

The report on Wearable Diabetes Devices covers a summarized study of several factors supporting market growth, such as market size, market type, major regions, and end-user applications. The report enables customers to recognize key drivers that influence and govern the market.

According to Cognitive Market Research, the global glucose monitoring devices market was valued at USD XX in 2023 and it is expected to grow at a CAGR of XX% from 2024 to 2029.

The global software engineering market will grow significantly by XX% CAGR between 2024 to 2029.
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market.
The report includes an analysis of the regional as well as market trends, key players, application areas, and market growth strategies.
Detailed analysis of Market Drivers, Restraints and Opportunities
North America dominated the market and accounted for the highest revenue of XX% in 2023 and it is projected that it will grow at a CAGR of XX% in the future.
The report consists size of the market.

Market Dynamics of Glucose Monitoring Devices

Key Drivers

Improving device synchronized data and accuracy for monitoring the glucose level drives the glucose monitoring device market

One of the most important aspects of the monitoring device is the accuracy with which it measures glucose levels. Accurate glucose monitoring is critical for successful diabetes management because it directly influences treatment decisions and patient outcomes. Several companies have developed advanced versions of conventional blood glucose monitors that are portable and minimally invasive. Many next-generation solutions include connectivity features that allow patients' health data to be captured and shared with medical professionals upon request. Companies are doing continuous innovation on the product for giving exact data to the customers. For Instance, in June 2024 Roche Holding AG receives CE mark for its AI enabled continuous glucose monitoring solution offering critical predictions to people living with 1 and type 2 diabetes n flexible insulin therapy. (source https://www.stocktitan.net/news/RHHBY/roche-receives-ce-mark-for-its-ai-enabled-continuous-glucose-i6j95ac2d9ie.html) Modern devices can now provide reliable and consistent readings, lowering the risk of complications caused by incorrect glucose measurements. Exact readings give patients more control over their blood glucose levels, resulting in fewer episodes of hyperglycemia or hypoglycemia. The development of continuous glucose monitoring (CGM) systems marks a significant technological advancement. Furthermore, accurate glucose monitoring devices are critical for healthcare providers because they allow for precise monitoring and individualized treatment plans. This can lead to more efficient resource utilization and improved patient outcomes, thereby driving market growth. As technology advances, glucose monitoring devices' accuracy is expected to improve even more, solidifying their role in effective diabetes management and expanding their global adoption.

Rising number of diabetes patients will further boost the glucose monitoring devices market

The growing incidence of diabetes among populations in both developed and undeveloped countries is leading to a large patient pool worldwide requiring blood monitoring, leading to an increase in demand for these devices among the patient population. Several factors, including rapid urbanization and the rising shift toward a sedentary lifestyle, in emerging and developed countries are primarily responsible for the growing prevalence of diabetes. For Instance, according to International Diabetes Federation (IDF) in 2021, it was estimated that around 537 million adults had diabetes, and China, India, U.S.A., Brazil and Mexico accounted for an estimated 51.6% of the global diabetes population in 2021. (source https://diabetesatlas.org/#:~:text=Diabetes%20around%20the%20world%20in%202021%3A,%2D%20and%20middle%2Dincome%20countries) A significant increase has been observed in the number of patients suffering from type-1 or insulin-dependent type 2 diabetes, which has been instrumental in surging the uptake of glucose monitoring systems globally. Thus, the presence of a large diabetic population with insulin-dependent diabetes, new product introductions by market players, and favorable reimbursement are driving demand and adoption of glucose monitoring devices

Restraints

The high cost of devices hinders the market growth

The glucose monitoring device is expensive and can be painful. Diabetes care devices do not always produce accurate results. Many hospitals and health...

The Latin America Diabetes Devices Market size was valued at USD 18.58 billion in 2023 and is projected to reach USD 30.87 billion by 2032, exhibiting a CAGR of 7.52 % during the forecasts period. The Latin America diabetes devices market comprises those devices that are utilized to measure and regulate diabetes such as glucose meter, insulin pump, CGM systems and insulin pen. Many of these items are used to aid in the treatment of diabetes by helping the patient to check on their blood glucose levels, give themselves insulin, and increase the control of their illness in general. Major factors that exist in the market include latest technologies like combined smartphone applications for tracking data, introduction and usage of minimally invasive CGM systems, and growth in diabetes care expenditures and knowledge of the inhabitants of the region. The market is mainly buoyed by the increasing rates of diabetes and.factor that seek to improve convenience and effectiveness of the patient. Recent developments include: In October 2023, Philips-Medisize teamed up with GlucoModicum to design and commercialize a proprietary non-invasive, wearable device that removes technology and patient-care roadblocks in continuous glucose monitoring (CGM). , In October 2022, BD signed an agreement with Biocorp intending to use connected technology to track self-monitored drug adherence and outcomes such as biologics, by using Near Field Communication (NFC) technology , In June 2022, Abbott announced the development of a Novel Continuous Gloucose-Ketone Monitoring System which is one of a kind biowearable device. the device enables diabetic people to monitor glucose and ketones continuously in one sensor only .

Explore the growth potential of Market Research Intellect's Home Diabetes Care Device Market Report, valued at USD 12.5 billion in 2024, with a forecasted market size of USD 22.3 billion by 2033, growing at a CAGR of 8.2% from 2026 to 2033.

The size of the South Korea Diabetes Care Devices Market market was valued at USD 457.06 Million in 2023 and is projected to reach USD 562.13 Million by 2032, with an expected CAGR of 3.00% during the forecast period. Currently, South Korea diabetes care devices market is in growth phase due to increasing diabetes cases along with increased awareness for proper management of diseases. Diabetes care devices are those instruments and apparatus that have been used for the monitoring of blood glucose level and it comprises of glucose meter, insulin delivery systems, continuous glucose monitoring systems and test strips. There are technological factors that currently form the market including the incorporation of health digital platforms and also enhancement of accuracy in the monitoring devices. In addition, factors such as a rising incidence of chronic diseases, a surge in the healthcare spending, and a higher level of adoption of government policies to curb diabetes and other diseases and a growing population of geriatrics add to the growth of the market. New trends include the use of wearables and integration of the device with real-time mobile applications feed. Recent developments include: January, 2023: Adela (Online Selling website for Abbott Free Style Libre in Korea) announced that the freestyle libre selling price is expected to be raised by 10% in Korea, due to continuous raise in raw materials and inflation., May 2022: EOFlow a provider of wearable drug delivery solutions announced the official launch of the iOS Version of 'Narsha,' a smartphone application for wearable insulin pumps in Korea.. Key drivers for this market are: Rising Prevalence of Cancer Worldwide, Technological Advancements in Diagnostic Testing; Increasing Demand for Point-of-care Treatment. Potential restraints include: High Cost of Molecular Diagnostic Tests, Lack of Skilled Workforce and Stringent Regulatory Framework. Notable trends are: Self-Monitoring Blood Glucose Devices occupy the highest market share in the monitoring devices segment in South Korea Diabetes Care Devices Market in the current year.

Market Size and Growth: The China Diabetes Devices Market is projected to grow from a value of USD 1.89 billion in 2025 to USD 3.35 billion by 2033, registering a CAGR of 9.11%. The increasing prevalence of diabetes in China, driven by factors such as urbanization, sedentary lifestyles, and unhealthy diets, is fueling the market growth. The government's emphasis on healthcare infrastructure development and insurance policies covering diabetes treatments further supports market expansion. Key Trends and Drivers: The Chinese Diabetes Devices Market is witnessing significant technological advancements, with the emergence of continuous glucose monitoring (CGM) devices and personalized insulin delivery systems. The adoption of these devices improves diabetes management efficiency, leading to better patient outcomes. Additionally, the government's initiatives to promote innovative medical technologies encourage the development and commercialization of novel diabetes devices. This, coupled with the growing awareness of diabetes prevention and management, drives the market's growth. The China diabetes devices market is a rapidly growing industry, driven by the increasing prevalence of diabetes in the country. In 2023, the market was valued at USD 12.5 billion and is expected to reach USD 19.5 billion by 2030, exhibiting a CAGR of 5.6% during the forecast period (2023-2030). This growth is attributed to factors such as the rising incidence of diabetes, increasing awareness about the disease, and technological advancements in diabetes management devices. Recent developments include: In June 2024, Novo Nordisk received approval from China's National Medical Products Administration (NMPA) for its type 2 diabetes treatment, Ozempic (semaglutide). The drug, a GLP-1 receptor agonist, has demonstrated effectiveness in controlling blood sugar levels and aiding weight loss. , In June 2023, AstraZeneca's Xigduo XR, a once-daily fixed-dose combination of the SGLT2 inhibitor dapagliflozin and metformin extended-release, was approved by China's NMPA for treating adults with type 2 diabetes. This approval offers a new therapy to address the significant unmet need for effective and convenient treatments that can help reduce complications and improve adherence in this patient population. , In November 2021, Microtech Medical Co., Ltd. received approval for its Continuous Glucose Monitoring (CGM) system device, AiDEX G7 from the National Medical Products Administration in China. This innovative device aims to enhance diabetes management by providing real-time glucose monitoring, improving patient outcomes, and facilitating better blood sugar control for individuals with diabetes. , In October 2021, EOFlow, a leading developer of wearable drug delivery systems, and Medtronic, a global leader in healthcare technology, announced a joint venture “SINOFLOW Co., Ltd.” to increase the presence of this companies in the country’s large diabetes management market, which includes various medical devices. , In May 2021, Metronom Health and Dinova Medtech formed a joint venture to launch a continuous glucose monitoring (CGM) device in China. This CGM system utilizes proprietary Opto-enzymatic technology, offering a minimally invasive alternative to traditional fingerstick meters, providing continuous glucose data with high accuracy. The device aims to enhance patient comfort and reduce infection risks, with a sensor lifespan of up to 14 days. .

Diabetes Wearables Market Outlook

The global diabetes wearables market size was estimated at USD 10.5 billion in 2023 and is projected to reach approximately USD 22.8 billion by 2032, exhibiting a CAGR of 9.0% during the forecast period. The market is driven by the increasing prevalence of diabetes worldwide, technological advancements in diabetes management devices, and the rising adoption of wearable health technologies among diabetic patients.

The rising incidence of diabetes globally serves as a significant growth factor for the diabetes wearables market. According to the International Diabetes Federation (IDF), the prevalence of diabetes is expected to increase from 463 million in 2019 to 700 million by 2045. This alarming rise in diabetes cases necessitates the need for effective and convenient diabetes management solutions, thereby propelling the demand for diabetes wearables. These devices offer real-time monitoring and ease of use, making them an attractive option for diabetes management.

Technological advancements in the field of diabetes management have also significantly contributed to the market growth. Innovations such as continuous glucose monitors (CGMs), smart insulin pens, and insulin pumps offer enhanced accuracy, better user interface, and integration with other digital health platforms. The incorporation of artificial intelligence and machine learning algorithms in these devices has further improved their efficiency, providing personalized insights and recommendations for better diabetes control. These technological strides are expected to continue driving market growth in the coming years.

Additionally, the growing awareness and adoption of wearable health technologies among diabetic patients is another key factor fueling the market growth. Wearable devices provide a convenient means for patients to monitor their glucose levels and manage insulin administration without frequent visits to healthcare facilities. The COVID-19 pandemic has further accelerated the adoption of telehealth and remote monitoring solutions, including diabetes wearables, as patients seek to minimize physical interactions and manage their health from the safety of their homes.

Implantable Diabetes Sensors are emerging as a groundbreaking innovation within the diabetes wearables market. These sensors offer a unique advantage by providing continuous glucose monitoring without the need for frequent replacements or external attachments. Unlike traditional wearables, implantable sensors are designed to be minimally invasive and can remain in the body for extended periods, offering consistent and reliable data. This technology is particularly beneficial for individuals who require constant glucose monitoring but prefer a more discreet solution. As research and development in this area continue to advance, implantable diabetes sensors are expected to become a vital component of diabetes management, offering enhanced convenience and accuracy for users.

The regional outlook for the diabetes wearables market shows significant potential across various regions. North America currently holds the largest market share, driven by a high prevalence of diabetes, favorable reimbursement policies, and the presence of key market players. Europe follows closely, with substantial growth expected due to increasing healthcare expenditure and technological adoption. The Asia Pacific region is anticipated to witness the highest growth rate, driven by a surge in diabetes cases, increasing healthcare awareness, and government initiatives to improve diabetes management. Latin America and the Middle East & Africa regions also show promising growth potential, albeit at a slower pace compared to other regions.

Product Type Analysis

The diabetes wearables market is segmented into various product types, including continuous glucose monitors (CGMs), insulin pumps, smart insulin pens, and others. Continuous glucose monitors (CGMs) represent a significant portion of the market due to their ability to provide real-time glucose readings. These devices are highly accurate and convenient, reducing the need for frequent finger-prick blood tests. The integration of CGMs with smartphones and other digital platforms allows for better data management and remote monitoring by healthcare providers, enhancing their appeal and adoption among diabetic patients.

Insulin pumps are another critical segment within the diabetes wearables market. These devi

Diabetes Management Devices Market Outlook

The global diabetes management devices market size was valued at approximately USD 26.5 billion in 2023 and is projected to reach around USD 49.8 billion by 2032, growing at a compound annual growth rate (CAGR) of 7.2% from 2024 to 2032. This growth can be attributed to the increasing prevalence of diabetes, coupled with the rising demand for advanced medical technologies to monitor and manage this chronic condition effectively. The global upsurge in diabetic cases, driven by lifestyle changes, aging populations, and genetic predispositions, forms a significant growth factor. Furthermore, the growing awareness regarding self-monitoring of blood glucose and the potential of technology-driven interventions in diabetes care are expected to propel the market forward over the forecast period.

One of the primary growth drivers for the diabetes management devices market is the rising incidence of diabetes worldwide. Sedentary lifestyles, unhealthy dietary habits, and increasing obesity rates have contributed significantly to the growing diabetic population. The World Health Organization (WHO) estimates that by 2030, diabetes will be the seventh leading cause of death. As the prevalence of diabetes rises, the demand for effective management solutions also increases, creating a robust market for diabetes management devices. Innovations in technology, such as continuous glucose monitoring and closed-loop insulin delivery systems, have transformed diabetes management, offering patients more precise control over their blood glucose levels and improving overall quality of life.

Technological advancements in diabetes management devices have led to the development of more sophisticated and user-friendly devices, further driving market growth. The integration of artificial intelligence (AI) and cloud-based solutions has enabled real-time data tracking and personalized treatment plans, enhancing patient engagement and compliance. Moreover, the proliferation of smartphone applications and wearable technologies has made it easier for patients to monitor their glucose levels and insulin administration remotely. These advancements not only improve patient outcomes but also reduce healthcare costs by minimizing complications associated with poor diabetes management, thus boosting the market for diabetes management devices.

Public health initiatives and government support play a crucial role in the expansion of the diabetes management devices market. Many countries have implemented national diabetes prevention and control programs aimed at raising awareness, promoting early diagnosis, and providing access to affordable diabetes care. For instance, the U.S. government's National Diabetes Prevention Program emphasizes lifestyle changes and routine screenings to prevent or delay the onset of type 2 diabetes. Such initiatives increase the adoption of diabetes management devices as part of comprehensive diabetes care strategies. Additionally, favorable reimbursement policies and coverage for diabetes management devices encourage patients to utilize these technologies, further driving market growth.

From a regional perspective, North America currently dominates the diabetes management devices market, owing to its high diabetes prevalence, advanced healthcare infrastructure, and strong presence of key market players. However, the Asia Pacific region is expected to witness the fastest growth during the forecast period, driven by a rising diabetic population, increasing healthcare expenditure, and growing awareness about diabetes management. Emerging markets such as India and China present significant opportunities for market expansion due to their large patient populations and improving access to healthcare services. Moreover, the Middle East and Africa region also demonstrate potential for growth, supported by efforts to improve healthcare systems and address the rising burden of diabetes.

The market for Pet Diabetes Care Devices Sales is also witnessing a notable surge, as awareness about diabetes in pets increases among pet owners. With advancements in veterinary medicine, there is a growing emphasis on the health and wellness of pets, including the management of chronic conditions like diabetes. Pet diabetes care devices, such as glucose monitors and insulin delivery systems, are becoming more sophisticated, mirroring the technological progress seen in human diabetes care. This segment is driven by the rising incidence of diabetes in pets, particularly in cats and dogs, which is often linked

Millimeter Wave Diabetes Treatment Devices Market Outlook

The global market size for millimeter wave diabetes treatment devices was estimated to be approximately $1.5 billion in 2023, and it is predicted to reach $3.2 billion by 2032, reflecting a compound annual growth rate (CAGR) of about 8.5%. A significant growth factor driving this market is the increasing prevalence of diabetes worldwide, which has created an urgent demand for innovative and efficient management solutions. Millimeter wave technology, known for its ability to provide precise monitoring and non-invasive treatment options, is emerging as a cornerstone in diabetes care, offering new hope for millions of individuals managing this chronic condition.

The millimeter wave technology in diabetes treatment devices is gaining traction due to its potential to revolutionize how diabetes is monitored and managed. Traditional methods of diabetes management often involve invasive procedures, but millimeter wave devices offer a non-invasive alternative that significantly improves patient comfort and compliance. This innovative approach not only enhances the quality of life for patients but also fosters better disease management, potentially reducing the long-term complications associated with diabetes. As healthcare systems worldwide continue to shift towards patient-centric approaches, the demand for such non-invasive technologies is expected to grow, further propelling the market forward.

Another key growth factor is the technological advancements in wearable health monitoring devices. Wearable millimeter wave diabetes treatment devices provide real-time data analytics, enabling continuous monitoring of glucose levels without the need for constant finger pricking or other invasive methods. These advancements are particularly appealing to active individuals who require continuous glucose monitoring but wish to avoid the inconvenience of traditional methods. Additionally, the integration of artificial intelligence and machine learning algorithms into these devices allows for more accurate predictions of glucose trends and personalized treatment plans, further enhancing their appeal and driving market growth.

The increasing investment in healthcare infrastructure, particularly in emerging markets, is also a significant driver of market growth. Governments and private sectors are investing heavily in advanced healthcare technologies to improve the quality of care and accessibility for diabetic patients. Such investments often include funding for the development and distribution of innovative devices like those using millimeter wave technology. As these technologies become more accessible and affordable, especially in countries with high diabetes prevalence, the market for millimeter wave diabetes treatment devices is poised for significant expansion.

Regionally, North America holds a substantial share of the millimeter wave diabetes treatment devices market, driven by the high prevalence of diabetes and the availability of advanced healthcare infrastructure. However, the Asia Pacific region is expected to witness the fastest growth, with a notable CAGR, due to the increasing incidence of diabetes and rising health consciousness among the population. The rapid urbanization and changing lifestyles in countries like China and India have contributed to a surge in diabetes cases, creating a substantial demand for advanced treatment solutions. Furthermore, government initiatives aimed at improving diabetes care and management in these regions are likely to bolster market growth over the forecast period.

Product Type Analysis

Within the millimeter wave diabetes treatment devices market, product type is a critical segment that comprises wearable and non-wearable devices. Wearable devices are currently leading the market due to their convenience, ease of use, and the growing trend of health monitoring through smart technology. These devices can continuously monitor glucose levels, providing real-time data to both patients and healthcare providers. The increasing integration of smart technology into healthcare devices has significantly enhanced the functionality of wearables, making them a preferred choice for patients seeking efficient diabetes management solutions.

Wearable millimeter wave devices offer a unique advantage in diabetes management, particularly with their ability to integrate with smartphones and other personal devices. This connectivity allows users to track their health metrics seamlessly, fostering a proactive approach to diabetes management. Furthermore, the development of aesthetically appealing and

Snapshot img

Digital Diabetes Management Market Size 2024-2028

The global digital diabetes management market size is estimated to grow by USD 19.12 billion at a CAGR of 21.99% between 2023 and 2028. The digital diabetes market refers to the use of technology and digital tools in managing and monitoring diabetes. Diabetes, a chronic condition, arises when the body struggles to utilize insulin effectively or when the pancreas fails to produce adequate insulin. Elevated blood sugar levels, known as hyperglycemia, pose significant risks and can lead to severe complications if left unmanaged. The growing popularity of digital diabetes management stands as a key driver fueling market growth. Digital diabetes management can be enhanced by integrating automatic pill dispensing systems, ensuring timely medication and improving patient adherence. As diabetes prevalence escalates globally, there is an increasing demand for effective management solutions to improve patient outcomes and mitigate healthcare expenses. Digital diabetes management encompasses the utilization of technological tools such as wearables, smartphone applications, and cloud-based platforms for monitoring and managing diabetes effectively.

What will be the Size of the Market During the Forecast Period?

To learn more about this report, Request Free Sample

Market Segmentations

The market is witnessing significant growth driven by advancements in technology and increasing demand for innovative solutions. Cloud-based enterprise solutions and artificial intelligence (AI) technologies are revolutionizing diabetes care by leveraging big data analytics and machine learning algorithms to provide personalized insights and predictions for patients. Smart insulin pens and wearable medical devices enable convenient insulin monitoring and blood glucose monitoring systems, empowering patients to manage their condition effectively. Healthcare providers benefit from AI-driven solutions that offer exercise guidance and closed-loop pumps, enhancing treatment outcomes and patient care. With a growing geriatric population, the demand continues to rise, highlighting the importance of technological innovation in improving the lives of diabetes patients.

End-user Analysis

The market share growth by the hospitals segment will be significant during the forecast period. The hospital segment of the market refers to the use of digital tools and technology to manage and treat diabetes in a hospital setting. This segment includes various digital solutions such as mobile applications, online platforms, electronic health records (EHRs), medical devices, and telehealth services that are used by healthcare professionals and patients to manage diabetes.

Get a glance at the market contribution of various segments View a PDF Sample

The hospitals segment was valued at USD 1.77 billion in 2018. Some of the key aspects of the hospital segment in the market include remote patient monitoring, diabetes education, and self-management, electronic health records (EHRs), telehealth services, medical device integration, data analytics, and decision support. By adopting digital tools and technologies, hospitals can provide more personalized care, improve access to healthcare services, and empower patients to actively participate in their diabetes management, which will drive the growth of the market during the forecast period.

Type Analysis

Wearable devices for diabetics include continuous glucose monitoring (CGM) systems and insulin pumps, which help to manage their blood sugar levels much more effectively and easily. Wearable devices were originally developed for people with type 1 diabetes, but technological advances have expanded their use in type 2 diabetics. Moreover, growth in the number of regulatory approvals for CGM systems and the development of advanced wearable products such as closed-loop pump systems and smart insulin patches will further enhance the growth of the wearable devices segment of the market during the forecast period.

Regional Analysis

For more insights about the market share of various regions View PDF Sample now!

North America is estimated to contribute 46% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. With the increasing incidence in the region, there is a high demand for innovative solutions to manage and monitor this disease. Additionally, the region's demand for telemedicine platforms and remote patient monitoring devices is driven by the need for remote monitoring and virtual consultations.

Furthermore, favorable government programs and regulatory frameworks are also fostering market growth. North America is home to a number of significant market participants, such as Medtronic, Dexcom, Abbott Laboratories, Insulet Corporation, and Livo

The Continuous Glucose Monitoring (CGM) Systems market is experiencing robust growth, projected to reach $4745.5 million in 2025 and maintain a Compound Annual Growth Rate (CAGR) of 19.7% from 2025 to 2033. This significant expansion is driven by several key factors. The increasing prevalence of diabetes globally, coupled with advancements in CGM technology leading to improved accuracy, smaller device sizes, and enhanced user-friendliness, are major contributors. Furthermore, the rising demand for convenient and non-invasive blood glucose monitoring solutions, particularly among younger and elderly populations, fuels market growth. The integration of CGM data with other health management platforms and applications further enhances its appeal, enabling proactive diabetes management and better patient outcomes. This market segment is characterized by significant technological innovation, with companies continuously striving to improve the accuracy, longevity, and comfort of their devices. The market is witnessing a surge in demand for wearable and implantable CGMs, reflecting the preference for less invasive and more convenient monitoring options. The market segmentation reveals a diverse landscape, with variations in demand across different age groups (child, adult, elderly) and device types (wearable, implantable). North America, particularly the United States, currently holds a significant market share due to high diabetes prevalence and advanced healthcare infrastructure. However, emerging economies in Asia-Pacific and other regions are experiencing rapid growth, driven by increasing diabetes awareness and expanding access to healthcare. Competition is fierce, with established players like Dexcom, Abbott Laboratories, and Medtronic vying for market share alongside innovative smaller companies. Future growth will depend on continuous innovation in sensor technology, improved data analytics, and broader adoption of integrated diabetes management solutions. The regulatory landscape also plays a vital role, with approvals and reimbursements influencing market access and adoption rates. The long-term outlook for the CGM market remains exceptionally positive, propelled by the unmet medical needs of a growing diabetic population and the continuous advancements in the technology.

The South Korea Diabetes Drugs and Devices Market was valued at USD 3.5 Billion in 2024 and is projected to reach USD 5.2 Billion by 2032, growing at a CAGR of 5.0% from 2026 to 2032.

The South Korea Diabetes Drugs and Devices Market is driven by the rising prevalence of diabetes due to aging populations, sedentary lifestyles, and dietary changes. Government initiatives, favorable reimbursement policies, and increasing healthcare expenditure are boosting market growth. Technological advancements in insulin delivery systems, continuous glucose monitoring (CGM), and wearable diabetes management devices are improving patient outcomes. The growing adoption of digital health solutions, telemedicine, and AI-driven analytics for personalized diabetes care further accelerates market expansion. Additionally, the presence of key pharmaceutical and medical device companies, along with increasing awareness campaigns, is supporting sustained market growth.

The size of the Diabetes Care Devices Market in Mexico market was valued at USD 503 Million in 2023 and is projected to reach USD 755.33 Million by 2032, with an expected CAGR of 5.98% during the forecast period.Diabetes care devices are very important tools to aid diabetic patients to manage their disorder. They help monitor blood sugar levels, administer insulin and log food intake. Blood glucose meters measure the blood sugar; patients can then take corrective action with their dosages of insulin or change their dieting habits. Insulin pumps administer insulin continuously or at programmed intervals, thereby providing greater accuracy for blood sugar control. Continuous glucose monitors monitor blood sugar levels throughout the day, though they measure in real time, they reduce the number of finger pricks needed for carbohydrate quantities. More amazingly, people have monitoring devices that record carbohydrate intake and calculate how much insulin is needed. All this has greatly improved the quality of life for the people affected with diabetes as it is almost impossible for better disease management, prevention of complications, and improved overall well-being. Recent developments include: October 2022: Becton, Dickinson, and Company and Biocorp signed an agreement to use connected technology to track adherence to self-administered drug therapies, like biologics. To support biopharmaceutical companies in their efforts to improve the adherence and outcomes of injectable drugs, the two companies will integrate Biocorp's Injay technology. It is a solution designed to capture and transmit injection events using Near Field Communication technology to the BD UltraSafe Plus Passive Needle Guard used with pre-fillable syringes., June 2022: Abbott announced that it's developing a new bio-wearable that will continuously monitor glucose and ketone levels in one sensor. The glucose-ketone sensor will be the same size as Abbott's FreeStyle Libre 3 sensor, the world's smallest and thinnest continuous glucose monitoring sensor. It will connect to Abbott's digital ecosystem, including personal and caregiver mobile apps and cloud-based data management software for remote monitoring by healthcare professionals.. Key drivers for this market are: Rising Prevalence of Cancer Worldwide, Technological Advancements in Diagnostic Testing; Increasing Demand for Point-of-care Treatment. Potential restraints include: High Cost of Molecular Diagnostic Tests, Lack of Skilled Workforce and Stringent Regulatory Framework. Notable trends are: Continuous glucose monitoring segment is expected to witness highest growth rate over the forecast period.

The South Korea diabetes care devices market, valued at $457.06 million in 2025, is projected to experience steady growth, driven by increasing prevalence of diabetes, rising geriatric population, and improving healthcare infrastructure. The market's Compound Annual Growth Rate (CAGR) of 3% from 2019 to 2033 indicates a consistent, albeit moderate, expansion. Key growth drivers include the increasing adoption of advanced technologies like continuous glucose monitoring (CGM) systems and insulin pump therapy, which offer improved diabetes management and better quality of life for patients. While the market faces restraints such as high device costs and potential reimbursement challenges, these are partially offset by government initiatives promoting better diabetes care and increased awareness campaigns targeting early diagnosis and effective management. The market segmentation shows a diverse landscape, with self-monitoring blood glucose devices and insulin pens dominating current sales, while CGM devices are expected to gain significant traction in the coming years, fueled by technological advancements and increasing patient preference for real-time glucose monitoring. Major players like Medtronic, Terumo, Novo Nordisk, and Abbott Diabetes Care are actively involved in developing innovative products and expanding their market presence through strategic partnerships and collaborations. This market's future trajectory will depend heavily on factors such as government regulations, technological innovations, and the evolving healthcare landscape in South Korea. Increased insurance coverage for advanced diabetes care devices could significantly boost market growth. Furthermore, the development of more user-friendly and affordable technologies, along with effective public health campaigns aimed at raising diabetes awareness and promoting early detection, will likely further stimulate market expansion. The competitive landscape will remain dynamic, with companies focusing on product differentiation, clinical trials, and partnerships to secure market share. The consistent CAGR, coupled with the aforementioned drivers and challenges, paints a picture of sustained, albeit manageable, growth for the South Korean diabetes care devices market over the forecast period. Recent developments include: January, 2023: Adela (Online Selling website for Abbott Free Style Libre in Korea) announced that the freestyle libre selling price is expected to be raised by 10% in Korea, due to continuous raise in raw materials and inflation., May 2022: EOFlow a provider of wearable drug delivery solutions announced the official launch of the iOS Version of 'Narsha,' a smartphone application for wearable insulin pumps in Korea.. Key drivers for this market are: Rising Prevalence of Cancer Worldwide, Technological Advancements in Diagnostic Testing; Increasing Demand for Point-of-care Treatment. Potential restraints include: High Cost of Molecular Diagnostic Tests, Lack of Skilled Workforce and Stringent Regulatory Framework. Notable trends are: Self-Monitoring Blood Glucose Devices occupy the highest market share in the monitoring devices segment in South Korea Diabetes Care Devices Market in the current year.

The Continuous Blood Glucose Monitoring (CGM) Devices market is experiencing robust growth, driven by increasing prevalence of diabetes, technological advancements leading to improved accuracy and user-friendliness, and rising demand for better diabetes management solutions. The market size in 2025 is estimated at $8 billion, reflecting a significant expansion from previous years. Considering a conservative Compound Annual Growth Rate (CAGR) of 15% throughout the forecast period (2025-2033), the market is projected to reach approximately $25 billion by 2033. This growth is fueled by several key factors, including the increasing adoption of minimally invasive and wearable CGMs among both adults and children, alongside the development of sophisticated algorithms for data analysis and personalized treatment recommendations. The aging global population further contributes to market expansion, as the elderly are particularly susceptible to diabetes and benefit greatly from continuous monitoring. Despite considerable growth, the market faces some challenges, including the relatively high cost of CGM devices, which can limit accessibility in certain regions and demographics. Regulatory hurdles and reimbursement policies in different countries also affect market penetration. Furthermore, potential accuracy limitations in specific conditions and the need for ongoing calibration in some devices remain areas for improvement and innovation. However, ongoing research and development efforts aimed at overcoming these challenges, coupled with increasing awareness about the benefits of CGM technology, point towards continued market expansion in the coming years. The market segmentation by device type (wearable, implantable) and user demographics (child, adult, elderly) offers diverse opportunities for manufacturers to cater to specific needs and preferences within the market.

The Europe Diabetic Care Devices Market is projected to reach a value of 8.03 million by 2025, exhibiting a CAGR of 6.18% during the forecast period 2019-2033. Growth in the market is attributed to factors such as the increasing prevalence of diabetes, growing awareness about blood glucose monitoring, and technological advancements in diabetic care devices. The rising incidence of diabetes coupled with the surging geriatric population are major factors driving the growth of the Europe Diabetic Care Devices Market. Moreover, government initiatives and reimbursement policies are further contributing to market growth. Key trends influencing market growth include the increasing adoption of continuous glucose monitoring devices, the integration of mobile health technology, and the growing focus on personalized diabetes management. However, factors such as high costs associated with diabetic care devices, potential risks associated with their usage, and the availability of generic drugs may restrain market growth to some extent. The Europe Diabetic Care Devices Market is segmented based on monitoring devices, management devices, companies, and region. The monitoring devices segment is further sub-segmented into self-monitoring blood glucose devices and continuous glucose monitoring devices. The self-monitoring blood glucose devices segment holds a significant market share due to the wide use of glucometer devices by diabetic patients. The insulin pumps segment is expected to witness significant growth during the forecast period due to the rising adoption of insulin therapy. Recent developments include: Feburary 2024: Dexcom launched real-time CGM solution Dexcom ONE+ in Europe. Dexcom ONE+ is a customisable continuous glucose monitoring solution that can be worn at three different location on the body., June 2022: Cequr, the leader in wearable diabetes technology, released its newest and most innovative insulin delivery device, the Insulin Pen 2.0TM. The pen is small enough to be always worn on the user's body, and it also features a built-in blood glucose meter so that users can track their blood sugar throughout the day.. Key drivers for this market are: Increasing Demand for Better Dentistry and Better Aesthetic outcomes, Increase in the Disposable Income. Potential restraints include: High Cost Associated with the Digital Dentistry. Notable trends are: The continuous glucose monitoring segment is expected to witness the highest growth rate over the forecast period.

The size of the U.S. Continuous Glucose Monitoring Devices Market market was valued at USD 1.62 billion in 2023 and is projected to reach USD 2.55 billion by 2032, with an expected CAGR of 6.68 % during the forecast period. The U. S. Continuous Glucose Monitoring (CGM) Devices Market is aimed at portable devices that can track the glucose levels of diabetic patients in real-time manner. These devices use a system to monitor glucose level every now and then at different time inclusive of day and night with trends and alarms for high and low glucose. They are also employed in diabetes care to enhance the management of diabetes and control the patients’ glycemic profiles. The market is continuously experiencing the uptake of CGM systems because they are accurate, convenient and new technologies like the integration of the systems with smartphones and insulin pumps. Some of the important trends include demand for wearable devices, the evolution of sensors and increasing consciousness of consumers about diabetes. Recent developments include: In February 2024, DexCom announced the launch of a unique CGM device, DexCom ONE+ in Europe. This device would allow real-time monitoring of blood glucose to users through a smartphone app. , In January 2024, Abbott and Tandem Diabetes Care, Inc. recently announced that their t:slim X2 insulin pump, which uses Control-IQ technology, has become the first Automated Insulin Delivery (AID) system to integrate with Abbott's latest Continuous Glucose Monitoring (CGM) technology, the FreeStyle Libre 2 Plus sensor. This development has enabled users of FreeStyle Libre technology in the U.S. to experience the benefits of a hybrid closed-loop system. With this system, users can predict and prevent high & low blood sugar levels , In October 2023, Phillips-Medisize announced the collaboration with GlucoModicum to present a non-invasive CGM wearable device to provide better patient outcomes. , In February 2023, Dexcom launched the Dexcom G7 CGM System in the U.S. It introduced the CGM system through a Super Bowl commercial starring Nick Jonas, who has diabetes. The commercial was expected to be watched by over 4.8 million diabetic U.S. individuals, of which 3.3 million were not using CGM and 2.3 million had CGM coverage. Hence, the ad was expected to create awareness about diabetes and have an influential product launch. .

The size and share of this market is categorized based on Insulin Delivery Devices (Insulin Syringes, Insulin Pens, Insulin Pumps, Smart Insulin Pens, Continuous Glucose Monitors) and Blood Glucose Monitoring Devices (Blood Glucose Meters, Continuous Glucose Monitors, Test Strips, Lancets, Smartphone-Enabled Meters) and Diabetes Management Software (Data Management Software, Mobile Health Applications, Telehealth Solutions, Diabetes Education Platforms, Cloud-Based Solutions) and Wearable Diabetes Devices (Smartwatches, Fitness Trackers, Wearable Glucose Monitors, Smart Clothing, Wearable Insulin Delivery Systems) and Combination Devices (Insulin Delivery with Monitoring, Smart Insulin Pens with Apps, Integrated Diabetes Management Systems, Closed Loop Systems, Smart Health Devices) and geographical regions (North America, Europe, Asia-Pacific, South America, Middle-East and Africa).